Find trials
Consejos para buscar

A Study to Evaluate the Spectrum of Healthy Pediatric Inflammatory Responses to Vaccinations

Overview

Información sobre este estudio

The purpose of this study is to understand the role of systemic inflammation in the genesis of seizures in susceptible children by gaining a clearer understanding of the spectrum of inflammatory responses that occur in healthy children post-vaccinations.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Group 1: children 5-7 months of age receiving the 3rd scheduled DTap-IPV/Hib+PCV13 dose.
  • Group 2: children 10-18 months of age receiving the 1st scheduled MMR+VZV dose.
  • Group 3: children 4-6 years of age receiving the 2nd scheduled MMR+VZV dose.
  • Group 4: children 0-12 years of age receiving the influenza vaccine or nasal mist.
  • Group 5: children 0-12 years of age receiving the SARS-CoV-2 vaccine.
  • Group 6: children in any of the above groups that were scheduled for a clinical vaccination after their first research blood collection, but it was cancelled by the provider for any reason.
  • Group 7: young adults 18-21 years of age receiving the influenza vaccine or nasal mist or SARS-CoV-2 vaccine.

Exclusion Criteria:

  • History of autoinflammatory or autoimmune disease.
  • History of genetic or metabolic disorder.
  • History of hematological disorder.
  • History of malignancy or active malignancy undergoing suppressive treatment.
  • Blood donation or collection within 8 weeks of the study.
  • Signs or symptoms consistent with severe infection at the time of first visit.
  • Weight less than 6 kg in group 1, less than 7.5 kg for group 2, less than 12 kg for group 3 and less than 6 kg for groups 4 & 5.
  • Additional vaccination within 3 weeks prior to baseline blood draw.

Eligibility last updated 2/11/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Charles Howe, Ph.D.

Abierto para la inscripción

Contact information:

Center for Multiple Sclerosis and Autoimmune Neurology

DLCMSANResCoor@mayo.edu

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20456377

Mayo Clinic Footer